Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Mallinckrodt Pharmaceuticals
18 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Transaction
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million
PR-M09-19-NI-037
M&A
Mallinckrodt and Silence Therapeutics Announce Collaboration to Develop And Commercialize RNAi Therapeutics for Complement-Mediated Diseases
PR-M07-19-NI-059
Generics
Mallinckrodt Modifies Specialty Generics Spinout Portfolio Composition
PAO-M06-19-NI-004
Generics
Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders
PR-M05-19-NI-087
Research
Mallinckrodt Presents Data on Cutaneous T-cell Lymphoma at 2019 American Academy of Dermatology Annual Meeting
PR-M03-19-NI-013
Spin-off Business
Mallinckrodt Spins off its Generics Business
PAO-M12-18-NI-005-11
Rheumatology
Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 ACR/ARHP Annual Meeting
PR-M10-18-NI-092
Skin Graft
Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns
PR-M10-18-NI-063
Licensing Agreement
Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt
PR-M09-18-NI-008
Collaborative Research Partnership
Mallinckrodt Forms Collaborative Research Partnership with Washington University in St. Louis
PR-M08-18-NI-056
Clinical Data
Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target
PR-M07-18-NI-009
Scientific Advisory Council
Mallinckrodt Launches Scientific Advisory Council
PR-M06-18-NI-081
FDA Acceptance
Mallinckrodt Receives FDA Acceptance of Stannsoporfin New Drug Application Filing
PR-M02-18-NI-106
Clinical Trials
Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue
PR-M02-18-NI-74
Acquisition
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
PR-M02-18-NI-62
Acquistion
Mallinckrodt Expands Rare Disease Pipeline with Sucampo Acquisition
PAO-M01-18-NI-017
Acquisition
Mallinckrodt Expands Pipeline with Ocera Therapeutics Buy
PAO-M11-17-NI-020
Acquisition
Mallinckrodt Acquires InfaCare Pharmaceutical Corporation for $425 Million
PAO-M08-17-NI-023
.svg)
